Treg depletion followed by intracerebral CpG-ODN injection induce brain tumor rejection

Journal of Neuroimmunology

Volumn 267, Issue 1-2, 2014, Pages 35-42

  Jarry, Ulrich ^a,b,c   Donnou, Sabrina ^a,b   Vincent, Marie ^a,b,c   Jeannin, Pascale ^a,b,c,d   Pineau, Laurent ^a,b   Fremaux, Isabelle ^a,b,c   Delneste, Yves ^a,b,c,d   Couez, Dominique ^a,b,c  

^a UNIVERSITÉ D'ANGERS   (France)

^b UMR892   (France)

^c UMR 6299   (France)

^d ANGERS UNIVERSITY HOSPITAL   (France)

Author keywords

CNS tumor; CpG ODN; NK cells; Treg

Indexed keywords

CPG OLIGODEOXYNUCLEOTIDE; ETOPOSIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; B LYMPHOCYTE; BRAIN LYMPHOMA; CANCER IMMUNOTHERAPY; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DENDRITIC CELL; DISEASE ASSOCIATION; DRUG EFFECT; IMMUNE RESPONSE; LYMPHOCYTE FUNCTION; MEMORY T LYMPHOCYTE; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; T CELL DEPLETION; TUMOR REJECTION;

CNS TUMOR; CPG-ODN; NK CELLS; PAMP; PATHOGEN RECOGNITION RECEPTOR; PATHOGEN-ASSOCIATED MOLECULAR PATTERN; PRR; TREG;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES; ANTIGENS, LY; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BRAIN NEOPLASMS; CELL LINE, TUMOR; CELL SURVIVAL; CYTOKINES; DISEASE MODELS, ANIMAL; ETOPOSIDE; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; KILLER CELLS, NATURAL; LYMPHOMA; MEMORY DISORDERS; MICE; MICE, INBRED C57BL; NEOPLASM TRANSPLANTATION; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY B; OLIGODEOXYRIBONUCLEOTIDES; T-LYMPHOCYTES, REGULATORY; TIME FACTORS; TOLL-LIKE RECEPTOR 9;

EID: 84893683456     PISSN: 01655728     EISSN: 18728421     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2013.12.005     Document Type: Article

References (57)

1. Alizadeh D., Zhang L., Brown C.E., Farrukh O., Jensen M.C., Badie B. Induction of anti-glioma natural killer cell response following multiple low-dose intracerebral CpG therapy. Clin. Cancer Res. 2010, 16:3399-3408.
2. Bailey S.L., Carpentier P.A., McMahon E.J., Begolka W.S., Miller S.D. Innate and adaptive immune responses of the central nervous system. Crit. Rev. Immunol. 2006, 26:149-188.
3. Ballas Z.K. Modulation of NK cell activity by CpG oligodeoxynucleotides. Immunol. Res. 2007, 39:15-21.
4. Beauvillain C., Donnou S., Jarry U., Scotet M., Gascan H., Delneste Y., et al. Neonatal and adult microglia cross-present exogenous antigens. Glia 2008, 56:69-77.
5. Billiard F., Litvinova E., Saadoun D., Djelti F., Klatzmann D., Cohen J.L., et al. Regulatory and effector T cell activation levels are prime determinants of in vivo immune regulation. J. Immunol. 2006, 177:2167-2174.
6. Bode C., Zhao G., Steinhagen F., Kinjo T., Klinman D.M. CpG DNA as a vaccine adjuvant. Expert Rev. Vaccin. 2011, 10:499-511.
7. Bouaziz J.D., Yanaba K., Tedder T.F. Regulatory B cells as inhibitors of immune responses and inflammation. Immunol. Rev. 2008, 224:201-214.
8. Buckner J.C., Brown P.D., O'Neill B.P., Meyer F.B., Wetmore C.J., Uhm J.H. Central nervous system tumors. Mayo Clin. Proc. 2007, 82:1271-1286.
9. Calzascia T., Di Berardino-Besson W., Wilmotte R., Masson F., de Tribolet N., Dietrich P.Y., et al. Cutting edge: cross-presentation as a mechanism for efficient recruitment of tumor-specific CTL to the brain. J. Immunol. 2003, 171:2187-2191.
10. Carpentier A., Laigle-Donadey F., Zohar S., Capelle L., Behin A., Tibi A., et al. Phase 1 trial of a CpG oligodeoxynucleotide for patients with recurrent glioblastoma. Neuro-Oncology 2006, 8:60-66.
11. Carpentier A., Metellus P., Ursu R., Zohar S., Lafitte F., Barrie M., et al. Intracerebral administration of CpG oligonucleotide for patients with recurrent glioblastoma: a phase II study. Neuro-Oncology 2010, 12:401-408.
12. Dalpke A.H., Schafer M.K., Frey M., Zimmermann S., Tebbe J., Weihe E., et al. Immunostimulatory CpG-DNA activates murine microglia. J. Immunol. 2002, 168:4854-4863.
13. DiLillo D.J., Yanaba K., Tedder T.F. B cells are required for optimal CD4+ and CD8+ T cell tumor immunity: therapeutic B cell depletion enhances B16 melanoma growth in mice. J. Immunol. 2010, 184:4006-4016.
14. Donnou S., Fisson S., Mahe D., Montoni A., Couez D. Identification of new CNS-resident macrophage subpopulation molecular markers for the discrimination with murine systemic macrophages. J. Neuroimmunol. 2005, 169:39-49.
15. El Andaloussi A., Han Y., Lesniak M.S. Prolongation of survival following depletion of CD4+CD25+ regulatory T cells in mice with experimental brain tumors. J. Neurosurg. 2006, 105:430-437.
16. El Andaloussi A., Sonabend A.M., Han Y., Lesniak M.S. Stimulation of TLR9 with CpG ODN enhances apoptosis of glioma and prolongs the survival of mice with experimental brain tumors. Glia 2006, 54:526-535.
17. Grauer O., Poschl P., Lohmeier A., Adema G.J., Bogdahn U. Toll-like receptor triggered dendritic cell maturation and IL-12 secretion are necessary to overcome T-cell inhibition by glioma-associated TGF-beta2. J. Neuro-Oncology 2007, 82:151-161.
18. Grauer O.M., Nierkens S., Bennink E., Toonen L.W., Boon L., Wesseling P., et al. CD4+FoxP3+ regulatory T cells gradually accumulate in gliomas during tumor growth and efficiently suppress antiglioma immune responses in vivo. Int. J. Cancer 2007, 121:95-105.
19. Grauer O.M., Molling J.W., Bennink E., Toonen L.W., Sutmuller R.P., Nierkens S., et al. TLR ligands in the local treatment of established intracerebral murine gliomas. J. Immunol. 2008, 181:6720-6729.
20. Grauer O.M., Sutmuller R.P., van Maren W., Jacobs J.F., Bennink E., Toonen L.W., et al. Elimination of regulatory T cells is essential for an effective vaccination with tumor lysate-pulsed dendritic cells in a murine glioma model. Int. J. Cancer 2008, 122:1794-1802.
21. Gursel M., Verthelyi D., Klinman D.M. CpG oligodeoxynucleotides induce human monocytes to mature into functional dendritic cells. Eur. J. Immunol. 2002, 32:2617-2622.
22. Hornung V., Rothenfusser S., Britsch S., Krug A., Jahrsdorfer B., Giese T., et al. Quantitative expression of toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides. J. Immunol. 2002, 168:4531-4537.
23. Jack C.S., Arbour N., Manusow J., Montgrain V., Blain M., McCrea E., et al. TLR signaling tailors innate immune responses in human microglia and astrocytes. J. Immunol. 2005, 175:4320-4330.
24. Jacobs J.F., Idema A.J., Bol K.F., Grotenhuis J.A., de Vries I.J., Wesseling P., et al. Prognostic significance and mechanism of Treg infiltration in human brain tumors. J. Neuroimmunol. 2010, 225:195-199.
25. Johnson L.A., Sampson J.H. Immunotherapy approaches for malignant glioma from 2007 to 2009. Curr. Neurol. Neurosci. Rep. 2010, 10:259-266.
26. Koo G.C., Peppard J.R. Establishment of monoclonal anti-Nk-1.1 antibody. Hybridoma 1984, 3:301-303.
27. Kranzer K., Bauer M., Lipford G.B., Heeg K., Wagner H., Lang R. CpG-oligodeoxynucleotides enhance T-cell receptor-triggered interferon-gamma production and up-regulation of CD69 via induction of antigen-presenting cell-derived interferon type I and interleukin-12. Immunology 2000, 99:170-178.
28. Lenert P.S. Classification, mechanisms of action, and therapeutic applications of inhibitory oligonucleotides for Toll-like receptors (TLR) 7 and 9. Mediat. Inflamm. 2010, 2010:986596.
29. Liau L.M., Prins R.M., Kiertscher S.M., Odesa S.K., Kremen T.J., Giovannone A.J., et al. Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment. Clin. Cancer Res. 2005, 11:5515-5525.
30. Loser K., Beissert S. Regulatory T cells: banned cells for decades. J. Invest. Dermatol. 2012, 132:864-871.
31. Masson F., Calzascia T., Di Berardino-Besson W., de Tribolet N., Dietrich P.Y., Walker P.R. Brain microenvironment promotes the final functional maturation of tumor-specific effector CD8+ T cells. J. Immunol. 2007, 179:845-853.
32. Meng Y., Carpentier A.F., Chen L., Boisserie G., Simon J.M., Mazeron J.J., et al. Successful combination of local CpG-ODN and radiotherapy in malignant glioma. Int. J. Cancer 2005, 116:992-997.
33. Pellegatta S., Poliani P.L., Stucchi E., Corno D., Colombo C.A., Orzan F., et al. Intra-tumoral dendritic cells increase efficacy of peripheral vaccination by modulation of glioma microenvironment. Neuro-Oncology 2010, 12:377-388.
34. Pere H., Montier Y., Bayry J., Quintin-Colonna F., Merillon N., Dransart E., et al. A CCR4 antagonist combined with vaccines induces antigen-specific CD8+ T cells and tumor immunity against self antigens. Blood 2011, 118:4853-4862.
35. Reichmann G., Schroeter M., Jander S., Fischer H.G. Dendritic cells and dendritic-like microglia in focal cortical ischemia of the mouse brain. J. Neuroimmunol. 2002, 129:125-132.
36. Ricard D., Idbaih A., Ducray F., Lahutte M., Hoang-Xuan K., Delattre J.Y. Primary brain tumours in adults. Lancet 2012, 379:1984-1996.
37. Rivest S. Regulation of innate immune responses in the brain. Nat. Rev. Immunol. 2009, 9:429-439.
38. Roda J.M., Parihar R., Carson W.E. CpG-containing oligodeoxynucleotides act through TLR9 to enhance the NK cell cytokine response to antibody-coated tumor cells. J. Immunol. 2005, 175:1619-1627.
39. Sakaguchi S. Regulatory T, cells: history and perspective. Methods Mol. Biol. 2011, 707:3-17.
40. Sampson J.H., Schmittling R.J., Archer G.E., Congdon K.L., Nair S.K., Reap E.A., et al. A pilot study of IL-2Ralpha blockade during lymphopenia depletes regulatory T-cells and correlates with enhanced immunity in patients with glioblastoma. PLoS One 2012, 7:e31046.
41. Shalev I., Schmelzle M., Robson S.C., Levy G. Making Sense of Regulatory T cell Suppressive Function. Semin. Immunol. 2011 Aug, 23(4):282-292. (Epub 2011 May 17). 10.1016/j.smim.2011.04.003.
42. Shirota Y., Shirota H., Klinman D.M. Intratumoral injection of CpG oligonucleotides induces the differentiation and reduces the immunosuppressive activity of myeloid-derived suppressor cells. J. Immunol. 2012, 188:1592-1599.
43. Sun J.C., Lanier L.L. Natural killer cells remember: an evolutionary bridge between innate and adaptive immunity?. Eur. J. Immunol. 2009, 39:2059-2064.
44. Sun J.C., Lopez-Verges S., Kim C.C., DeRisi J.L., Lanier L.L. NK cells and immune "memory". J. Immunol. 2011, 186:1891-1897.
45. Tadokoro C.E., Shakhar G., Shen S., Ding Y., Lino A.C., Maraver A., et al. Regulatory T cells inhibit stable contacts between CD4+ T cells and dendritic cells in vivo. J. Exp. Med. 2006, 203:505-511.
46. Tripp C.H., Ebner S., Ratzinger G., Romani N., Stoitzner P. Conditioning of the injection site with CpG enhances the migration of adoptively transferred dendritic cells and endogenous CD8+ T-cell responses. J. Immunother. 2010, 33:115-125.
47. Triulzi C., Vertuani S., Curcio C., Antognoli A., Seibt J., Akusjarvi G., et al. Antibody-dependent natural killer cell-mediated cytotoxicity engendered by a kinase-inactive human HER2 adenovirus-based vaccination mediates resistance to breast tumors. Cancer Res. 2010, 70:7431-7441.
48. Van Gool S., Maes W., Ardon H., Verschuere T., Van Cauter S., De Vleeschouwer S. Dendritic cell therapy of high-grade gliomas. Brain Pathol. 2009, 19:694-712.
49. Vauleon E., Avril T., Collet B., Mosser J., Quillien V. Overview of cellular immunotherapy for patients with glioblastoma. Clin. Dev. Immunol. 2010, 2010.
50. Vivier E., Tomasello E., Baratin M., Walzer T., Ugolini S. Functions of natural killer cells. Nat. Immunol. 2008, 9:503-510.
51. Vollmer J., Krieg A.M. Immunotherapeutic applications of CpG oligodeoxynucleotide TLR9 agonists. Adv. Drug Deliv. Rev. 2009, 61:195-204.
52. Wang C., Cao S., Yan Y., Ying Q., Jiang T., Xu K., et al. TLR9 expression in glioma tissues correlated to glioma progression and the prognosis of GBM patients. BMC Cancer 2010, 10:415.
53. Wieder T., Braumuller H., Kneilling M., Pichler B., Rocken M. T cell-mediated help against tumors. Cell Cycle (Georgetown, Tex.) 2008, 7:2974-2977.
54. Yamanaka R., Honma J., Tsuchiya N., Yajima N., Kobayashi T., Tanaka R. Tumor lysate and IL-18 loaded dendritic cells elicits Th1 response, tumor-specific CD8+ cytotoxic T cells in patients with malignant glioma. J. Neuro-Oncology 2005, 72:107-113.
55. Zarember K.A., Godowski P.J. Tissue expression of human Toll-like receptors and differential regulation of Toll-like receptor mRNAs in leukocytes in response to microbes, their products, and cytokines. J. Immunol. 2002, 168:554-561.
56. Zhou L., Chong M.M., Littman D.R. Plasticity of CD4+ T cell lineage differentiation. Immunity 2009, 30:646-655.
57. Zimmer J., Andres E., Hentges F. NK cells and Treg cells: a fascinating dance cheek to cheek. Eur. J. Immunol. 2008, 38:2942-2945.